Caveats of Bacterial Endotoxin Testing (single user digital version)
- Format
- PDF Single user
- Member Price
- $55.00
- Nonmember Price
- $69.00
- Government Price
- $30.00
This chapter is taken from the book Pharmaceutical Contamination Control: Practical Strategies for Compliance
A 'caveat' has been described as both a warning or caution, and a qualification or explanation. The word is used here with both meanings to help form a list of issues to have in mind when devising and performing tests for bacterial endotoxins. In its broadest sense the goal of such testing is to preclude the occurrence of significant levels of pyrogens from drugs, drug constituents, and drug containers/closures. Any oversight that impedes or lessens the likelihood of such preclusion or misjudges the levels that can be considered as ‘significant’ can be viewed as deserving of a caveat. Furthermore, any historical context or elaboration of test mechanism that broadens our views or deepens our understanding of the test deserves mention as well.
Available to download. Prior to purchase please view the download instructions and Terms of Usage.
Format: Digital PDF (1 file - 2.89 MB)
Table of Contents
Table of Contents:
About the Authors
About the Authors
Kevin Williams
is Associate Pharmacological Consultant. Eli Lilly & Co., Indianapolis,
Indiana. The author or co-author of several books and peer-reviewed articles.
Mr. Williams is a member of ASM International and the Parenteral Drug
Association. He received the BS degree (1982) from Texas A&M University,
College Station, USA.